01

Enpatoran Phase 2 Trial Reports Symptom Improvement in Cutaneous Lupus

An oral TLR7/8 inhibitor met its Phase 2 primary endpoint in cutaneous lupus erythematosus, per a Dermatology Advisor report, though full efficacy data remain unpublished.